Kaleido Biosciences Inc. (KLDO)

Overview

Kaleido Biosciences, Inc. is a pioneering clinical-stage healthcare company focused on the development of microbiome metabolic therapies (MMT). Founded in 2015 and based in Lexington, Massachusetts, the company leverages the potential of the human microbiome to create innovative treatments for a wide array of diseases and conditions. Through strategic collaborations with entities such as Institute Gustave Roussy, Washington University, and Janssen, Kaleido Biosciences seeks to transform the landscape of medical treatments with its groundbreaking approaches. The company’s research and development efforts are directed towards addressing unmet medical needs across various therapeutic areas, including urea cycle disorder, ulcerative colitis, hepatic encephalopathy, COVID-19, multi-drug resistant infections, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases.

Products and Services

• KB195

  Developed for the treatment of patients with urea cycle disorder, KB195 represents Kaleido Biosciences’ innovative approach to leveraging microbiome metabolic therapies to address this genetic disorder.

• KB295

  Targeting the treatment of ulcerative colitis, KB295 is a testament to the company's dedication to combating gastrointestinal diseases through the modulation of the microbiome.

• KB174

  For the treatment of hepatic encephalopathy, KB174 is designed to mitigate the cognitive impairments associated with severe liver diseases by restoring microbiome balance.

• KB109

  Responding to the global health crisis, KB109 is focused on treating COVID-19 disease, showcasing Kaleido Biosciences’ flexibility and responsiveness to emerging health challenges.

Additionally, Kaleido Biosciences is actively developing programs aimed at addressing multi-drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. Through these initiatives, the company is expanding its portfolio of microbiome metabolic therapies to provide novel treatment options across a broad spectrum of conditions.